PCSK9 inhibitors × cardiovascular events

TrialJournal of clinical lipidology

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.

Paul M Ridker et al.PubMed ↗Publisher ↗

What the trial testedas reported · 15,959 people

Range includes no effect

No clear effect on cardiovascular events

−17%−56% to +54%

2 in 100 instead of 3

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.83, 95% CI 0.44–1.54

One number in the abstract

the abstract, start to end

797 allocated to placebo (hazard ratio 0.83; 95% confidence interval

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.830.44–1.54
PCSK9 inhibitorsCardiovascular events

PCSK9 inhibitors × cardiovascular eventshelps?settled

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

25 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
pooled ittrialcites it

6 trials

Full record →Abstract, authors, funding and every citing paper · PMID 29685591